David Nikodem, Ph.D. | Chief Executive Officer
David joined AltheaDx in December 2018 as Interim CEO and then continued to permanent CEO in January 2020, leading the team to a successful reimbursement decision at CMS. He has served on the Board of Directors of AltheaDx since December 2015 as a representative of Ally Bridge Group, where he led a private investment for a syndicate of investors in 2015. Prior to AltheaDx, David was a healthcare industry investor, both in public equites, as well as venture capital, where he served on numerous Boards of Directors. He obtained his Ph.D. from Georgetown University and an undergraduate degree from The University of Virginia.
Feng Cao, Ph.D. | Chief Operating Officer
Feng joined AltheaDx in February 2015 with over fifteen years of experience in the molecular diagnostics space. Before expanding to lead Operations in April 2018, Feng was AltheaDx’s VP of Informatics, where he was responsible for the combined use of genetics, algorithm, and analytics to improve our IDgenetix® tests. Prior to joining AltheaDx, Feng held management positions at Hologic where he launched the Invader Call Reporter® product line for molecular diagnostic IVD tests such as Cystic Fibrosis 510(k), Factor II/V 510(k), and HPV PMA. Prior to the acquisition of Third Wave Technologies by Hologic, Feng worked with a team of scientists on sequence analysis, SNP selection, assay design, and order generation for over 500,000 SNPs in support of the successful completion of the International HapMap Project. Feng earned his doctorate in Cell Biology from Medical College of Wisconsin, his master’s degree in Computer Science from Marquette University, and his bachelor’s degree in Biology from Peking University.
Lou Almerini | CPA, CFO
Lou has over 30 years of experience in senior finance roles as CFO and/or Controller. He started his career at Price Waterhouse in New York City and joined Morgan Stanley as corporate controller where he led the development of the firm’s corporate and SEC reporting during its first nine years as a public company. Over 14 years at Merrill Lynch he held senior finance roles as a divisional controller and CFO, and most recently he served as deputy CFO at PineBridge Investments, an AIG carve-out. Lou is a principal with CFO Financial Partners, LLC. He is a graduate of Georgetown University and a Certified Public Accountant.
Jonathan Yount | SVP Sales and Marketing
With over 8 years of experience in pharmacogenomic testing and 15+ years in the healthcare field, Jonathan brings sales and marketing skills to AltheaDx. His prior experience has been driving success in the pharmacogenomics testing space as a Chief Growth Officer and U.S. Sales Leader. He has a M.S. degree from Purdue University and an undergraduate degree from Texas Christian University.
Adrianna Ravenscroft | Laboratory Manager
With 8+ years of experience as a licensed Clinical Laboratory Scientist, Adrianna Ravenscroft provides the know-how for managing a CLIA lab since she joined AltheaDx in 2014. Previous experience includes positions at UC San Diego Health System and Sharp Healthcare. Adrianna obtained a BA in Biology from University of Montana and her Clinical Laboratory Science Internship from UCSD.
Curtis McGuyer, M.D. | Laboratory Director
Dr. McGuyer joined AltheaDx in January 2019 as our Laboratory Director. Dr. McGuyer is also the Southwest Regional Commissioner for Laboratory Accreditation at College of American Pathologists (CAP). After fulfilling his military service obligation, Dr. McGuyer entered private practice and for 28 years worked as a community hospital pathologist in San Diego, California. His practice is now focused on clinical pathology, providing medical directorship to reference laboratories in San Diego. Dr. McGuyer received his M.D. from Baylor College of Medicine and his BS in Chemistry from University of Texas at El Paso. His residency was at Naval Hospital San Diego, where he completed his training in anatomic and clinical pathology. He is board-certified in both anatomic and clinical pathology, as well as cytopathology.